NCT00394433View on ClinicalTrials.gov

Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

November 30, 2008

Study Completion Date

October 31, 2016

Conditions
Esophageal CancerStomach Cancer
Interventions
DRUG

Bevacizumab

DRUG

Docetaxel

DRUG

Cisplatin

DRUG

Irinotecan

Trial Locations (3)

02114

Massachusetts General Hospital, Boston

02115

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Brigham and Women's Hospital

OTHER

collaborator

Massachusetts General Hospital

OTHER

collaborator

Genentech, Inc.

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER

NCT00394433 - Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer | Biotech Hunter | Biotech Hunter